See more : Maire Tecnimont S.p.A. (MT.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Biora Therapeutics, Inc. (BIOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biora Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IndusInd Bank Limited (INDUSINDBK.BO) Income Statement Analysis – Financial Results
- South Dakota Soybean Processors, LLC (SDSYA) Income Statement Analysis – Financial Results
- Samji Electronics Co., Ltd. (037460.KQ) Income Statement Analysis – Financial Results
- Oil India Limited (OIL.NS) Income Statement Analysis – Financial Results
- Sonoro Gold Corp. (SMOFF) Income Statement Analysis – Financial Results
Biora Therapeutics, Inc. (BIOR)
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M | 127.97M |
| Cost of Revenue | 0.00 | 907.00K | 1.44M | 93.43M | 100.49M | 92.08M |
| Gross Profit | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M | 35.90M |
| Gross Profit Ratio | 100.00% | -197.38% | -15.24% | -25.73% | 30.21% | 28.05% |
| Research & Development | 29.84M | 24.05M | 45.79M | 47.74M | 63.40M | 48.71M |
| General & Administrative | 0.00 | 0.00 | 68.54M | 75.44M | 61.32M | 51.24M |
| Selling & Marketing | 0.00 | 0.00 | 4.76M | 52.89M | 58.89M | 50.19M |
| SG&A | 37.31M | 38.04M | 73.30M | 128.33M | 120.21M | 101.43M |
| Other Expenses | 0.00 | 2.62M | 5.99M | -25.08M | 0.00 | 0.00 |
| Operating Expenses | 67.15M | 62.09M | 119.08M | 176.07M | 183.61M | 150.14M |
| Cost & Expenses | 67.15M | 62.09M | 119.08M | 269.50M | 284.10M | 242.21M |
| Interest Income | 0.00 | 10.99M | 12.64M | 9.92M | 575.00K | 1.80M |
| Interest Expense | 9.82M | 10.99M | 12.64M | 34.87M | 9.20M | 9.09M |
| Depreciation & Amortization | 555.00K | 907.00K | 1.44M | 1.44M | 4.60M | 4.60M |
| EBITDA | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M | -110.17M |
| EBITDA Ratio | -2,851,350.00% | -19,398.03% | -5,106.66% | -262.66% | -92.51% | -84.93% |
| Operating Income | -67.14M | -61.78M | -117.84M | -195.19M | -140.12M | -114.24M |
| Operating Income Ratio | -1,678,575.00% | -20,256.07% | -9,449.64% | -262.66% | -97.31% | -89.27% |
| Total Other Income/Expenses | -57.28M | 12.53M | -60.80M | -35.00M | -8.62M | -9.62M |
| Income Before Tax | -124.42M | -49.25M | -178.64M | -230.06M | -148.74M | -123.86M |
| Income Before Tax Ratio | -3,110,600.00% | -16,147.54% | -14,325.58% | -309.58% | -103.30% | -96.78% |
| Income Tax Expense | -90.00K | -420.00K | -119.00K | -37.53M | -706.00K | 5.25M |
| Net Income | -124.12M | -48.83M | -178.52M | -192.53M | -148.04M | -129.11M |
| Net Income Ratio | -3,102,875.00% | -16,009.84% | -14,316.04% | -259.08% | -102.81% | -100.88% |
| EPS | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| EPS Diluted | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| Weighted Avg Shares Out | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.
Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript
Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants...
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for...
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31,...
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at...
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is...
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet™ platform for oral, systemic delivery of...
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial...
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the...
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the...
Source: https://incomestatements.info
Category: Stock Reports